INTEGRATED PROTEINS LIMITED

Manek Centre,Office No 218,P N Marg,Jamnagar – 361008, Gujarat,India
Phone:9428817400
Email ID: integrated.pl2024@gmail.com
Website: www.integratedproteins.com
CIN: L62013GJ1992PLC018426

Date: 14/08/2026

To,
BSE Limited
Phiroz Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Ref : Scrip Code - 519606

Sub: Outcome of the meeting of the Board of Directors held on Friday, 14th August, 2026 pursuant to regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.

Dear Sir/Madam,

With reference to above subject and in compliance with Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Friday, 14th August, 2026, at the registered office of the company to consider and approve the Unaudited Financial Results for the Quarter ended on 30th June, 2026 along with the Limited Review Report by the auditors.

The aforesaid board meeting commenced at 13:00 HRS (IST) and concluded at 15:50 HRS (IST).

You are requested to take above on your records.

Thanking you,
Yours Faithfully,

For and on behalf of
INTEGRATED PROTEINS LIMITED

HIREN DHIRAJLAL SHAH
Digitally signed by HIREN DHIRAJLAL SHAH
Date: 2026.08.14 16:07:41 +05'30'

Hiren Shah
DIN: 09842161
MANAGING DIRECTOR

INTEGRATED PROTEINS LIMITED

CIN: L62013GJ1992PLC018426

Registered Office : Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Jamnagar, Gujarat, India, 361008

Unaudited Standalone Statement of Financial Results for the Quarter Ended 30-06-2026

(Rs. In Lakh except per share data)

	Particulars	Quarter Ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
A	Date of start of reporting period	01-04-2026	01-01-2026	01-04-2025	01-04-2025
B	Date of end of reporting period	30-06-2026	31-03-2026	30-06-2025	31-03-2026
C	Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Audited
D	Nature of report Standalone or Consolidated	Standalone	Standalone	Standalone	Standalone
Part I					
I	Revenue From Operations				
	Net sales or Revenue from Operations	1,054.73	569.03	-	993.57
II	Other Income	1.65	0.50	4.72	0.50
III	Total Income (I + II)	**1,056.38**	**569.53**	**4.72**	**994.07**
IV	Expenses				
(a)	Cost of materials consumed	-	-	-	-
(b)	Purchases of stock-in-trade	1,001.10	542.74	-	950.14
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
(d)	Employee benefit expense	1.02	0.54	0.68	3.16
(e)	Finance Costs	-	-	-	-
(f)	Depreciation and amortisation expense		-		
(g)	Other Expenses	5.81	3.11	4.04	12.43
	Total expenses	**1,007.93**	**546.39**	**4.71**	**965.74**
V	Profit (loss) before Exceptional and Extraordinary Items and tax (III-IV)	**48.45**	**23.14**	**0.01**	**28.33**
VI	Exceptional items				
VIII	Profit (loss) before Tax (V-VI)	**48.45**	**23.14**	**0.01**	**28.33**
X	Tax Expense				
(a)	Current Tax	12.19	4.14	-	5.83
	(Less):- MAT Credit	-	-	-	-
	Current Tax Expense Relating to Prior years	-	-	-	-
(b)	Deferred Tax (Asset)/Liabilities				
XI	Net Profit/Loss for the period from Continuing Operations (IX-X)	36.26	19.00	0.01	22.50
XII	Profit (Loss) from Discontinuing Operaitons	-	-	-	-
XIII	Tax Expenses of Discontinuing Operations	-	-	-	-
XIV	Net Profit (Loss) from Discontinuing Operartions after tax (XII-XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI+XIV)	36.26	19.00	0.01	22.50
XVI	Other Comprehensive Income				
	a. i).Amount of item that will not be reclassifed to profit or loss	-	-	-	-
	ii). Income tax relating to items that will not be reclassifed to profit or loss	-	-	-	-
	b. i). Item that will be reclassifed to profit or loss	-	-	-	-
	ii). Income tax relating to items that will be reclassifed to profit or loss	-	-	-	-
XVII	Total Comprehensive income	0.00	0.00	0.00	0.00
	Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)	36.26	19.00	0.01	22.50
XVIII	Details of equity share capital				
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	1,871.36	1,871.36	352.02	1,871.36
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
	Other Equity				

INTEGRATED PROTEINS LIMITED

XIX	Earnings per share (Not Annualized for Year ended)	0.19	0.10	0.00	0.12
(a)	Earnings per share Continuing Operation (Not Annualised for Year ended)				
	Basic earnings per share before extraordinary items	0.19	0.10	0.00	0.12
	Diluted earnings per share before extraordinary items	0.19	0.10	0.00	0.12
(b)	Earnings per share Discontinuing Operation (Not Annualised for Year ended)				
	Basic earnings per share after extraordinary items	0.00	0.00	0.00	0.00
	Diluted earnings per share after extraordinary items	0.00	0.00	0.00	0.00
(c)	Earnings per share (Not Annualised for Year ended)				
	Basic earnings per share before extraordinary items	0.19	0.10	0.00	0.12
	Diluted earnings per share before extraordinary items	0.19	0.10	0.00	0.12

Notes:-

Notes to Unaudited Standalone financials results for the quarter ended 30th June 2026:

1	The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards Amendment Rules 2016.
2	The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.
3	The Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 14 August , 2026
4	The Company has multiple reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".

INTEGRATED PROTEINS LIMITED

FOR, INTEGRATED PROTEINS LIMITED

Hiren Shah
Managing Director
DIN : 09842161

Date :- 14 August, 2026
Place :- Jamnagar

INTEGRATED PROTEINS LIMITED

CIN:L62013GJ1992PLC018426

Registered Office : Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jamnagar, Jamnagar, Gujarat, India, 361008

Reporting of Segment wise Revenue, Results and Capital Employed along financial results for the Quarter ended on June 30 , 2026

(₹ In Lakh except per share data)

	Particulars	Quarter ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
A	Date of start of reporting period	01-04-2026	01-01-2026	01-04-2025	01-04-2025
B	Date of end of reporting period	30-06-2026	31-03-2026	30-06-2025	31-03-2026
C	Whether results are audited or unaudited	Unaudited,	Audited	Unaudited	Audited
D	Nature of report standalone or consolidated	STANDALONE	STANDALONE	STANDALONE	STANDALONE
1	**Segment Revenue** (net sale/income from each segment should be disclosed under this head)				
(a)	Segment - Agro&Trading	1,051.23	17.78	-	437.60
(b)	Segment - Textile	-	461.63	-	461.63
(C)	Segment- Securities	3.50	89.62	4.72	94.34
(d)	Segment- Medical	0.50	0.50		0.50
(e)	Segment - Real estate	-	-	-	-
	Total	**1,055.23**	**569.53**	**4.72**	**994.07**
	Less: Inter Segment Revenue	-	-	-	-
	Net sales/Income From Operations	**1,055.23**	**569.53**	**4.72**	**994.07**
2	**Segment Results (Profit)(+)/ Loss (-) before tax and interest from Each segment)#**				
(a)	Segment - Agro&Trading	51.93	0.81	-	13.22
(b)	Segment - Textile	-	5.24	-	5.24
(C)	Segment- Securities	0.50	19.89	4.72	23.98
(d)	Segment- Medical	0.50	0.50		0.50
(e)	Segment - Real estate	-	-		-
(f)	Unallocable	1.15	-	-	-
	Total	**54.08**	**26.44**	**4.72**	**42.94**
	Finance Cost	5.63	3.30	4.71	14.61
	Other Un-allocable Expenditure net off	-	-	-	-
	Un-allocable income	5.63	3.30	4.71	14.61
		-	-	-	-
	Total Profit Before Tax	**48.45**	**23.14**	**0.01**	**28.33**
3	**Capital Employed (Segment assets - Segment Liabilities)**				
3(1)	**Segment Assets**				
(a)	Segment - Agro&Trading	67.17	26.18	0.70	26.18
(b)	Segment - Textile	-	184.70	-	184.70
(c)	Segment- Securities	1,376.11	1,531.32	1,750.31	1,531.32
(d)	Segment- Medical	150.00	150.00	-	150.00
(e)	Segment - Real estate	140.55	150.54	1,054.75	150.54
(g)	Unallocable	384.79	15.53	37.74	15.53
	Total	**2,118.62**	**2,058.27**	**2,843.50**	**2,058.27**
3(2)	**Segment Liabilities**				
(a)	Segment - Agro&Trading				
(b)	Segment - Textile	10.29			
(c)	Segment- Securities				
(d)	Segment- Medical				
(e)	Segment - Real estate				
(g)	Unallocable	19.40	15.63	836.35	15.63
	Total	**29.69**	**15.63**	**836.35**	**15.63**

For, Integrated Proteins Limited

INTEGRATED PROTEINS LIMITED

Hiren Dhirajlal Shah
Managing Director
DIN : 09842161

Date :-14-08-2026
Place:- Jamnagar

B.B. Gusani & Associates
Chartered Accountants

CA BHARGAV B. GUSANI
bhargavgusani77@gmail.com

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended)

To The Board of Directors of
Integrated Proteins Limited

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Integrated Proteins Limited** ("the Company") for the quarter ended 30th June 2026 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors at their meeting held on **14th August 2026**, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" (Ind AS 34), as prescribed under section 133 of the Companies Act, 2013 as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review of the Statement conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B B Gusani & Associates
Chartered Accountants

B.B. Gusani & Associates
M. No. 120710
Chartered Accountants

Bhargav B Gusani
Proprietor
Membership No. 120710
UDIN : 26120710PDUCZE9587
Date : 14th August 2026
Place : Jamnagar